Larch Arabinogalactan and vaccine response

What 2 graded rows on larch arabinogalactan agree on for vaccine response, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Larch Arabinogalactan page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Larch Arabinogalactan page, with its PubMed record.

Supplement

Larch Arabinogalactan Choose another

2 rows · 120 people

Inconsistent: both rows reported mixed results.

Mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

From the rows

The best-graded row, grade C, is a randomized trial of 75 people (2013) and reported mixed results.

Each row reported mixed results on its own, so there is no side to compare. The rows enrolled 45 to 75 people and were published from 2010 to 2013.

2 mixed

Grade CAntibody response to tetanus and flu vaccines · Mixed
RCT · n 75 · 2013 · Healthy adults aged 18 to 61 vaccinated against tetanus and influenza on day 30
1.5 g/day or 4.5 g/day · 60 days
At 1.5 g/day the rise in tetanus IgG at day 60 was greater than with placebo (p = 0.008); 4.5 g/day did not differ from placebo. Neither dose changed influenza antibodies compared with placebo. No serious adverse events.
Row on the Larch Arabinogalactan page · PubMed 24219376 (opens PubMed)
Grade CAntibody response to the pneumococcal vaccine · Mixed
Pilot RCT · n 45 · 2010 · Healthy adults not previously vaccinated against Streptococcus pneumoniae
4.5 g/day · 72 days (vaccine given on day 30)
IgG rose more than with placebo for 2 of 7 pneumococcal types (18C and 23F) at days 51 and 72; the other 5 types did not differ significantly. No effect on salivary IgA, white cell count, inflammatory cytokines or complement.
Row on the Larch Arabinogalactan page · PubMed 20796315 (opens PubMed)